Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina

Z. M. Galeeva; N. A. Andreichev

doi:undefined

Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina

Z. M. Galeeva, N. A. Andreichev

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Coronary heart disease (CHD) is the leading lethality cause in internal medicine. Up to 38% of the patients with coronary events die within the first year. Beta-adrenoblocker (BAB) therapy does not always provide adequate heart rate (HR) reduction. To reduce HR more effectively and, therefore, to increase anti-anginal effect, BAB could be combined with an If channel inhibitor (ivabradine). Effectiveness and safety of the ivabradine + BAB combination was studied in patients with effort angina. One clinical case is presented in detail.

Keywords

Effort angina, heart rate, ivabradine, beta-adrenoblockers

References

1. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 2006; 3(11): 442.

2. Steg PhG, Bhatt DL, Wilson PWF, et al. One year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-206.

3. Gillman M, Kannel W, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125: 1148-54.

4. Kannel W, Kannel C, Paffenbarger R, Cupples A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.

5. Kjekshus JK. Importance of heart rate in determining betablocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9.

6. Timolol-induced eduction in mortality and reinfarction in patients surviving acute myocardial infarction / The Norwegian Multicenter Study Group. N Eng J Med 1981; 304: 801-7.

7. Hjalmarson A, Gilpin E, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial inferction. Am J Sardiol 1990; 65: 547-53.

8. Benetos A, Thomas F, Bean K, et al. Resting heart rate in older people: a predictor of survival to age 85. J Am Geriart Soc 2003; 51: 284-5.

9. ESC Clinical Practice Guidelines. Cardiovascular Disease Prevention - Risk Assessment and Management / Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) [elektronnyi resurs] / Elektron. dan. - rezhim dostupa: www.escardio.org/guidelines-surveys/esc-guidelines//Pages/cvd-prevention.aspx, svobodnyi. - Zagl. s ekrana. - Yaz. angl.

10. Guidelines on the management of stable angina pectoris: executive summary/The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27 (11): 1341-81.

11. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-21.

12. Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 2002; 282: 672-9.

13. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284: 676-82.

14. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.

15. Erofeeva S.B., Maneshina O.A., Belousov Yu.B. Mesto ivabradina - pervogo If ingibitora izbiratel'nogo i spetsificheskogo deistviya v lechenii serdechno-sosudistykh zabolevanii. Kachestv klin prakt 2006; 1: 10-22.

16. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.

17. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.

18. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebocontrolled trial. The Lancet 372; 9641: 807-16.

19. Kjekshus J Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-8.

20. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.

For citations:

Galeeva Z.M., Andreichev N.A. Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina. Cardiovascular Therapy and Prevention. 2011;10(1):59-65. (In Russ.)

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

Cardiovascular Therapy and Prevention

Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

User

Cardiovascular Therapy and Prevention

Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy